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Voiding dysfunction is an uncommon condition in young men. With increased understanding of the
etiology of chronic lower urinary tract dysfunction, there has been signiﬁcant improvement in the
management of the condition. We have reviewed the current literature and make suggestions about
diagnosis, treatment, and further research on this topic. We searched the PubMed database for the
management of voiding dysfunction in young men using the following terms: voiding dysfunction, lower
urinary tract symptoms, young men, risk factor, urodynamics study, uroﬂowmetry, magnetic resonance
imaging, primary bladder neck obstruction/bladder neck dysfunction, dysfunctional voiding/pseudo-
dyssynergia, impaired detrusor contractility/detrusor underactivity, adrenergic antagonist, transurethral
incision, urotherapy, baclofen, and botulinum toxin. Uroﬂowmetry is an important noninvasive exami-
nation for screening young men for possible voiding dysfunction. A videourodynamic study is recom-
mended for patients with low urine ﬂow. Primary bladder neck obstruction and dysfunctional voiding
are the two most common diagnoses. a-Adrenergic antagonists and urotherapy are widely used for
treating bladder neck obstruction and dysfunctional voiding, respectively. Botulinum toxin A may
become a potential therapeutic option in the future. Although the published reports usually included a
small number of patients and lacked randomization and a placebo-controlled group, these clinical
studies still provide great advances in managing voiding dysfunction in young men. Further well-
designed studies are warranted to support optimal management of these conditions.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.Open access under CC BY-NC-ND license.1. Introduction
Voiding dysfunction is deﬁned by the International Continence
Society and International Urogynecological Association as
“abnormal, slow, and/or incomplete micturition” as diagnosed by
symptoms and urodynamic investigations.1 Abnormal, slow urine
ﬂow rates and abnormally high post-void residuals are the basis of
this diagnosis, which should be based on repeated measurements
to conﬁrm abnormality. Lower urinary tract symptoms (LUTSs) is
the term used to describe all types of voiding dysfunction, although
no such correlation exists between symptoms and underlying
pathophysiology.2 In older men, an enlarged prostate usually con-
tributes to LUTSs, but only about one-third of the men with LUTSs
>55 years of age meet the diagnostic criteria for benign prostatic
obstruction. About half of the men have detrusor overactivity and a
smaller number have detrusor underactivity.3 Although chronic
LUTSs are not uncommon, young men are usually empiricallyChu Kong Hospital, Number
iwan.
ng).
ciation. Published by Elsevier Taiwdiagnosed as having chronic prostatitis, prostatodynia, or psycho-
logical voiding dysfunction because of negative ﬁndings on the
physical or laboratory examinations.4,5 Consequently, the treat-
ments are usually empirical, and most physicians and patients
consider the results unsatisfactory. The purpose of this paper is to
review the current literature to ﬁnd accurate diagnostic techniques
for voiding dysfunction in young men and make recommendations
concerning treatment and further research.
2. Epidemiology
There is no consensus on the cutoff point between young men
and older men. Nitti et al6 arbitrarily deﬁned young men as aged
<45 years, whereas Wang et al7 from Taiwan and Toh and Ng8 from
Singapore deﬁned young men as aged 18e50 years. Karami et al9
used the narrowest range of age between 18 years and 40 years
to deﬁne young men.
2.1. Risk factors for voiding dysfunction in young men
To the best of our knowledge, there has not been a large,
community-based study to investigate the risk factors for chronican LLC. Open access under CC BY-NC-ND license.
Table 1
Summary of the videourodynamic study ﬁndings in young men with chronic voiding dysfunction.
Study Country Patient no. Patient age (mean, range, years) PBNO (%) DV (%) IDC (%) DO (%)
Kaplan et al, 19965 America 137 <50 54 24 17 49
Nitti et al, 20026 America 85 35.1, 18e45 47 14 9 6
Wang et al, 20037 Taiwan 90 37.5, 18e50 41 43 10 37
Toh and Ng, 20068 Singapore 50 38.1, 17e49 28 No data 10 18
Karami et al, 20119 Iran 456 25.8, 18e40 21 15 2 14
Data are presented as % unless otherwise indicated.
DO ¼ detrusor overactivity; DV ¼ dysfunctional voiding; IDC ¼ impaired detrusor contractility; PBNO ¼ primary bladder neck obstruction.
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dysfunctional voiding may arise in women who work long hours
and choosing not to urinate. Yang et al11 reported a similar ﬁnding
that 21% of young men with voiding dysfunction had habitually
neglected to urinate despite a full bladder because they were busy
with work. Fan et al12 showed that women (mean age 48 years)
with dysfunctional voiding experienced a greater degree of
depression and anxiety as compared to asymptomatic controls, but
the psychological proﬁles of young men with chronic voiding
dysfunction are unknown. In type 2 diabetic patients aged <45
years, even though the LUTSs are more common than in the control
group, the peak urinary ﬂow rate (Qmax) and post-void residual
(PVR) are similar in both groups, indicating that diabetes is not a
risk factor for voiding dysfunction in its early stages.13
2.2. Prevalence of voiding dysfunction e symptoms
Using a symptom-based deﬁnition, several epidemiological
surveys have revealed that the prevalence of all urinary symptoms
has increased linearly with age.14,15 The EPIC (European Prospective
Investigation of Cancer and Nutrition) study, an international,
cross-sectional study of 19,165 men and women, showed that the
prevalence of slow streamwas 3.9% in men aged <40 years, 7.4% in
men aged 40e59 years, and 18.9% in men aged >59 years.14 The
prevalence of any voiding symptom was 19.9%, 24.1%, and 37.2% in
men aged <40 years, 40e49 years, and 60 years, respectively. In
another study for young asymptomatic men, Mueller et al15 found
that 2% of men aged 18e29 years reported moderate symptoms
[International Prostrate Symptom Score (IPSS) >7] and 12% of men
aged 40e49 years also reported having moderate symptoms.
Interestingly, only 1% of men aged 18e29 years reported weak
stream, but of themen aged 40e49 years, 4% reportedweak stream.
Moon et al16 also surveyed 184 men aged 20e49 years from a Na-
tional Guard unit and reported that 5% of those aged 20e29 years,
12% of those aged 30e39 years, and 14% of those aged 40e49 years
had an IPSS of 8. These data suggest that although LUTSs in young
men are less common than in older men, bothersome LUTSs are not
as rare in young men as many physicians think.
2.3. Prevalence of voiding dysfunction e urodynamic studies
It is difﬁcult to identify the real pathophysiology of voiding
dysfunction based on symptoms alone. Although there is some
consensus regarding the deﬁnition of voiding symptoms, there is
no such consensus regarding urodynamic studies. The prevalence
of voiding dysfunction varies depending on the deﬁnition of Qmax
and PVR used. Wang et al7 deﬁned low uroﬂow Qmax as <15 mL/s.
Karami et al9 further demonstrated that Qmax, in most patients
with various voiding dysfunctions, was <15 mL/s. However, it is
difﬁcult to have a clear cutoff value of PVR to deﬁne voiding
dysfunction because many studies have shown a wide range of
PVRs in patients with voiding dysfunction.
The true prevalence of voiding dysfunction in the young male
population is unknown, because it is impossible and impracticalto perform a comprehensive urodynamic evaluation in a com-
munity setting. The best epidemiological ﬁndings available are
based on incidence rates in speciﬁc outpatient populations.
Table 15e9 summarizes the etiologies of chronic lower urinary
tract dysfunction in young men.5e9 In 1996, using video-
urodynamic study (VUDS) in 137 men aged <50 years with
chronic LUTSs, Kaplan et al5 retrospectively identiﬁed 74 (54%)
patients with primary bladder neck obstruction (PBNO), 33 (24%)
with dysfunctional voiding (DV), and 23 (17%) with impaired
detrusor contractility (IDC). In 2002, Nitti and colleagues6 pro-
spectively reported a 47% incidence of PBNO and 14% of DV in a
study of 85 men aged 18e45 years with LUTSs. Recently, in a
large prospective study of 456 men (18e40 years old) with
chronic LUTSs, Karami and colleagues9 reported PBNO in 96 cases
(21%), DV in 69 (15%), and underactive detrusor in 11 (2.4%).
These data would appear to support PBNO and DV as being the
two most common urodynamic diagnoses in young men with
chronic voiding dysfunction.
3. Diagnosing voiding dysfunction in young men
The diagnosis of voiding dysfunction in young men depends on
both thepatient’s symptomsandtheresults of the lowerurinary tract
investigations. LUTSs comprise storage symptoms, voiding symp-
toms, and post-micturition symptoms. However, clinical symptoms
are not helpful in predicting a speciﬁc urodynamic ﬁnding. In a
Taiwanese study, the IPSS of patients with PBNO was comparable
with the IPSS inpatientswithDV (20.3 5.5 vs.18.15.3, p¼ 0.87).7
Inan Iranianstudy, the IPSSof patientswithPBNOandDVwasalmost
identical (20.3  7.3 vs. 20.1  6.9, p ¼ 0.75).9
Several medical diseases may coexist in youngmenwith voiding
dysfunction. Symptoms of urinary tract infection, a positive uri-
nalysis, and urine culture results suggest cystitis or prostatitis.
History and signs of possible neurological diseases suggest neuro-
genic bladder. A voiding diary may disclose nocturnal polyuria and
global polyuria, which possibly imply many medical diseases, such
as diabetes mellitus, diabetic insipidus, and peripheral edema.
Radiological exams (kidney, ureter, and bladder X-ray ﬁlms) may
demonstrate vesical stones that usually occur in older men, but can
be found in youngmenwith voiding dysfunction. Youngmenwith a
vesical stone should be evaluatedwith uroﬂowmetry to identify the
possible voiding dysfunction.11 Nitti et al6 advocated that VUDSwas
a recommended test in young menwith abnormal urine ﬂow and a
high voiding score. Therefore, uroﬂowmetry is an important and
noninvasive examination to screen patients with possible voiding
dysfunction.
3.1. Videourodynamic studies
Without a doubt, VUDS is the most accurate diagnostic tool for
young men with chronic voiding dysfunction. VUDS adds the
anatomical perspective of lower urinary tract dysfunction to the
conventional urodynamic study. Using ﬂuoroscopic imaging, the
level of obstruction can be easily localized.
Fig. 1. Primary bladder neck dysfunction in a 46-year-old man with chronic lower urinary tract symptoms and low urinary ﬂow rate. This represents classic high-pressure, low-ﬂow
obstruction (arrowhead) with obstruction at the bladder neck when voiding on ﬂuoroscopy (arrow).
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agnoses.5e9 Traditionally, PBNO is deﬁned as a narrowing only at the
vesical neck on a ﬂuoroscopic voiding cystourethrogram, sustained
high detrusor pressure during voiding, low Qmax, obstructive ﬂow
pattern, and relaxed external sphincter electromyography.7 Fig. 1
shows a typical high-pressure, low-ﬂow obstructive pattern and
ﬂuoroscopy revealed a narrowing of the bladder neck during the
voiding phase. Nitti et al6 further categorized PBNO into three
distinct types: (1) classic high-pressure low ﬂow; (2) normal-
pressure low ﬂow with narrowing at the bladder neck; and, (3)
delayed opening of the bladder neck.6 All three conditions represent
vesical neck dysfunction causing an obstruction.
Dysfunctional voiding has been described by various terms
including external sphincter spasticity, nonrelaxing external urethral
sphincter, pseudodyssynergia, and learned voiding dysfunction. DV isFig. 2. Dysfunctional voiding in a 38-year-old man with chronic lower urinary tract symp
obstruction (large arrowhead) with obstruction at the external sphincter (large arrow) wh
arrowheads) during voiding is noted. In addition, cystometry tracing demonstrated the occ
activity (small arrow).deﬁned as an obstruction at the external sphincter determined by
intermittent narrowing of the membranous urethra on ﬂuoroscopy
and/or an intermittent increase in sphincter electromyography (EMG)
during a sustained voluntary detrusor contraction in the absence of
abdominal straining.7 Fig. 2 shows a 38-year-old man with DV and
detrusor overactivity. The VUDS showed involuntary detrusor
contraction during ﬁlling cystometry and high-pressure low-ﬂow
obstruction at the external sphincter when voiding on ﬂuoroscopy.
This diagnosis should be made in a neurologically normal man. The
same urodynamic ﬁnding inmenwith a known neurological disease
could be named as “detrusor external sphincter dyssynergia”.
Recently, the diagnostic criteria for DVweremodiﬁed by Brucker and
colleagues.17 They suggested that the urine ﬂow from VUDSmight be
correlated with the noninvasive urine ﬂow ﬁndings in patients with
DV. In cases in which intubated urine ﬂow suggested DV, but thetoms and staccato urinary ﬂow rate. This represents classic high-pressure, low-ﬂow
en voiding on ﬂuoroscopy. Intermittent increase in sphincter electromyography (small
urrence of involuntary detrusor contraction, which is compatible with detrusor over-
Table 2
Summary of results of a-blocker treatment in young men with primary bladder neck obstruction.
Trial Patient no. Medication and dose IPSS Qmax (mL/sec) PVR (mL)
Trockman et al, 199624 7 5 mg terazosin at bed time or
2 mg prazosin twice daily
Baseline: 18.6  4.6
Post-Tx: 10.3  9.9
Baseline: 11  3.6
Post-Tx: 22.1  13.9
Baseline: 65  62
Post-Tx: 45  30
Yang et al, 200211 24 Doxazosin 1 mg or 2 mg at bed time for 3 mo Baseline: 18.3  4.6
Post-Tx: 11.6  5.2
Baseline: 11.8  3.2
Post-Tx: 15.9  3.9
Baseline: 80  17
Post-Tx: 49  10
Cisternino et al, 200625 41 Alfuzosin 5 mg, tamsulosin 2 mg daily
Mean treatment time 16 mo (6e24)
Baseline: 18.6
Post-Tx: 10.3
Baseline: 8.5
Post-Tx: 14
Baseline: 64
Post-Tx: 40
Li et al26 24 Doxazosin 4 mg daily
Mean treatment time: 15.2 mo
Baseline: 17.7  4.2
Post-Tx: 10.1  4.7
Baseline: 11.4  2.9
Post-Tx: 15.4  3.6
Baseline: 79  33
Post-Tx: 50  23
Data are presented as mean  SD, unless otherwise indicated.
IPSS ¼ International Prostate Symptom Score; PVR ¼ postvoiding residuals; Post-Tx ¼ post-treatment; Qmax ¼ peak urinary ﬂow rate.
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induced, and these patients were not diagnosed with DV. Thus, in
doing VUDS, some investigators prefer a suprapubic catheter to a
transurethral one inorder to avoid increasing the sympathetic tone in
the male urethra induced by the urethral catheter.7 Therefore, PBNO
or DV may not be overdiagnosed.
Impaired detrusor contractility is deﬁned as a detrusor pressure
<30 cmH2O, Qmax <15 mL/s, and no obstruction identiﬁed
radiologically.7 In young men with symptomatic voiding dysfunc-
tion, 2e17% IDC has been present (Table 1). The common etiologies
of IDC in older men include diabetes mellitus, stroke, the aging
process, and untreated severe benign prostatic obstruction.
Widespread degeneration of muscle cells and axons, superimposed
on the dense band pattern, is proposed as the structural correlate
of IDC in the aging detrusor.18 However, the etiology in these
young populations was unclear because none of the patients had
obvious evidence of neurological disease or associated medical
comorbidities.3.2. Other diagnostic tools
Cystoscopy may be helpful in ﬁnding bladder trabeculation or
diverticulum, which is used to conﬁrm bladder outlet obstruction
or rule out other problems such as urethral stricture, urethral stone,
foreign bodies, or congenital posterior urethral valve. However, it
has little role in making a differential diagnosis of PBNO and DV.
The role of spinal magnetic resonance imaging (MRI) is limited
for detecting spinal cord lesions in patients with normal neuro-
logical and lower spine examinations. Mak and Rodomski19 pro-
spectively evaluated 30 patients (mean age 32.2 years) with voiding
dysfunction and normal neurological examinations. Of them, 18
had incontinence, nine had frequency and urgency alone, and three
had urinary retention. Only one patient had a tethered cord iden-
tiﬁed by MRI. Recently, Broughton et al20 have shown that the
diagnostic value of lumbosacral MRIs is extremely low (2%) in
children (mean age 8.5 years) with isolated dysfunctional elimi-
nation problems, and normal neurological, orthopedic, and back
examinations. Afshar et al21 further advocated that abnormal
cutaneous ﬁndings in the back are associated with abnormal MRI
ﬁndings. Although the probability of a positive MRI may be
increased with proper patient selection, a spinal MRI has a low
impact in the management of lower urinary tract dysfunction.4. Treatment of voiding dysfunction in young men
The treatment options for voiding dysfunction in young men
include watchful waiting, conservative treatment, medical treat-
ment, and surgical treatment. Watchful waiting is indicated in pa-
tients without obvious symptoms and without evidence of upper or
lower urinary tract function deterioration. Recently, Minassian et al22
have demonstrated that dysfunctional voiding in childhood maypredict bladder control problems as the child becomes a woman,
including urge incontinence and mixed incontinence. However, the
natural history in young men is unknown. In some cases, older men
with LUTSs that were presumed to be caused by an enlarged prostate
may have actually started their symptoms at a young age. Thus,
periodic follow-up with uroﬂowmetry and IPSS is suggested. If
subjective symptoms and/or objective voiding parameters get worse,
medical and/or surgical intervention are needed.4.1. Treatment for PBNO
Sympathetic nerve dysfunction has been suggested as the main
etiology of PBNO. Crowe et al23 found increased density in the
neuropeptide Y-immunoreactive nerves, part of the sympathetic
contractile system of the bladder, in patients with bladder neck
dysfunction. The adrenergic receptors are abundant in the bladder
neck, therefore, the mainstay of medical treatment of PBNO is an a-
blocker. Table 211,24e26 summarizes the changes in the urinary ﬂow,
PVR, and IPSS in several studies.11,24e26 Although a level-one evi-
dence trial in PBNO is lacking, these clinical observations all support
the possibility of a-blockers playing an important role in this regard.
The most effective surgical treatment is transurethral incision of
the bladder neck (TUIBN). TUIBN is suggested for patients when
medical treatment fails or when they seek a long-term therapeutic
effect. Turner-Warwick et al27 ﬁrst introduced the concept of
bladder neck incision in 1773. Consequently, Norlen and Blaivas28
reported the promising results of TUIBN in 23 patients with un-
suspected proximal urethral obstruction in 1986. Table 34,24,29e31
summarizes the surgical results of TUIBN in recent
studies.4,24,29,30 All reported that the patients had a decreased IPSS,
increased Qmax, and decreased PVR after TUIBN.
The main concern of TUIBN is postoperative retrograde ejacula-
tion in these young men with fertility concerns. Retrograde ejacu-
lation may occur in 27e100% of the patients receiving bilateral
TUIBN.4,24,29,30 Kochakarn et al31 demonstrated unilateral TUIBN had
a comparable outcome to bilateral TUIBN. However, they also re-
ported a signiﬁcant 70% reduction in sperm count from 59.2 million/
mL preoperatively to 18.1million/mL 1 year after surgery. Yang et al29
reported on a modiﬁed TUIBN, which preserves the prostate urethra
at 0.5e1.0 cm proximal to the verumontanum. All patients reported
antegrade ejaculation and improved voiding function. Moreover, the
International Index of Erectile Function scores did not change
signiﬁcantly during the 2-year follow-up. This clinical experience
suggests that preservation of the supramontanal tissue is the key
factor to maintaining antegrade ejaculation and sexual function
without jeopardizing the voiding function.4.2. Treatment of DV
Themainstay of treating DV is urotherapy, which is based on the
presumption that dysfunctional voiding may be a learned disorder
Table 3
Summary of therapeutic results after transurethral incision of the bladder neck in young men with primary bladder neck obstruction.
Study Mean patient
age (year)
Technique Follow up
(mo)
IPSS Qmax (mL/sec) PVR (mL) Complication
Kaplan et al, 19944
31 patients
39 Unilateral 6 30/31 improved Baseline: 9.2
Post-Tx: 15.7
No data No RE
Trockman et al, 199624
18 patients
41 Bilateral 12 Baseline: 17.2  5.2
Post-Tx: 4.3  4.5
Baseline: 8.2  4.5
Post-Tx: 26.7  11.8
Baseline:161  132
Post-Tx: 23  33
4/15 (73%) had RE
Kochakarn et al, 200331
35 patients
40 Unilateral 12 Baseline: 32.1  2
Post-Tx: 14.4 þ 3.6
Baseline: 7.8  2.2
Post-Tx: 15.2  1.6
No data Sperm count
decreased 70%
Yang et al, 200829
26 patients
42 Modiﬁed bilateral
5, 7 o’clock
24 Baseline: 20.7  5.7
Post-Tx: 8.7  4.7
Baseline: 10.7  3.7
Post-Tx: 19.2  4.6
Baseline: 107  77
Post-Tx: 48  25
No RE
No change in IIEF
Suri et al, 200530
18 patients
33 Unilateral
12 o’clock
96 Baseline: 26.9
Post-Tx: 3.6
Baseline: 8.5
Post-Tx: 19.6
No data 2/18 (11%) need
2nd TUIBN
Data are presented as mean  SD, unless otherwise indicated.
IIEF ¼ International Index of Erectile Function; IPSS ¼ International Prostate Symptom Score; PVR ¼ post-voiding residuals; Qmax ¼ peak urinary ﬂow rate; post-Tx ¼ post-
treatment; RE ¼ retrograde ejaculation.
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nonsurgical and nonpharmacological treatment, has been consid-
ered an effective treatment for dysfunctional voiding even though
there are no standardized protocols during the therapy. Basically,
urotherapy comprises education for the patient/family, adequate
ﬂuid intake, regular optimal voiding regimens, correcting toilet
posture, bowel programs, and importantly, pelvic ﬂoor muscle
awareness and biofeedback training. Several nonrandomized
studies in women and children have shown pelvic ﬂoor biofeed-
back training to be effective in treating voiding dysfunction. How-
ever, experience with this training in young men is extremely rare.
In 1997, Kaplan et al32 reported that 42 young men with pseudo-
dyssynergia (dysfunctional voiding) were misdiagnosed as chronic
nonbacterial prostatitis. Thirty-ﬁve of the patients (83%) had ach-
ieved improved symptoms at 6months, after behaviormodiﬁcation
and biofeedback.
Several encouraging studies have reported the efﬁcacy and
safety of a-blockers in children with dysfunctional voiding char-
acterized by increased PVR, staccato, or prolonged urine ﬂow, along
with elimination diaries.33 In children, a-blockers can facilitate
improved voiding and LUTSs. The beneﬁt of a-blockers can also be
seen in men with chronic nonbacterial prostatitis/chronic pelvic
pain syndrome which may overlap DV.34
Baclofen, a g-aminobutyric acid (GABA) agonist, is another
potentially effective medication for treating DV. GABAergic in-
terneurons in the spinal cord are responsible for the relaxation of the
external urethral sphincter during micturition, thus, baclofen can be
used to induce relaxation of the urethral sphincter to improve DV.
Although the mechanism of the micturition reﬂex supports the use
of baclofen, the clinical evidence is scarce. Xu and colleagues35
conducted a randomized double-blind, placebo-controlled cross-
over trial in 60 women with DV and LUTSs. A 4-week course of
baclofen 10mg three times daily signiﬁcantly reduced the number of
voids/day and increased Qmax. Further studies about dysfunctional
voiding in young men are needed in the future.
4.3. Treatment of IDC
Current standard pharmacotherapy for IDC includes the use of
muscarinic receptor agonists (e.g., bethanechol) or cholinesterase
inhibitors (e.g., distigmine). However, current evidence has shown
few beneﬁcial effects of these drugs and an unfavorable effect/side
effect proﬁle. In animal studies, capsaicin, resiniferatoxin, and
prostaglandin E2 may treat detrusor underactivity by increasing
detrusor strength or bladder sensation. However, the clinical ap-
plications are still unknown. Consequently, at this point no effective
pharmacotherapy for young men with IDC exists. Intermittent
clean self-catheterization is suggested in these patients.4.4. Botulinum toxin in young men with voiding dysfunction
Botulinum toxin (BoNT-A) has been widely used as a novel
therapy for various voiding dysfunctions. Lim and Quek36 ﬁrst
injected 100U BoNT-A in eight PBNO patients with a mean age of 37
years. The mean reduction of IPSS was 50% (19.9  2.7% vs.
9.9  1.7%, p ¼ 0.036) and Qmax increased from 11.6 mL/s to
17.2 mL/s (p ¼ 0.048). None reported any adverse effects or ejacu-
lation dysfunction. However, the long-term effect was limited and
three of the eight patients had recurrent symptoms after a mean 8
months.
Several clinical studies reported the application of BoNT-A in-
jection into the urethral sphincter to treat DV, IDC, and even chronic
urine retention.37 The beneﬁt of a BoNT-A injection has been
proven in spinal cord injury patients with detrusor sphincter dys-
synergia and in neurologically intact patients with DV. Kuo38
showed a very promising result in 27 patients with idiopathic
low detrusor contractility after an urethral injection of either 50 U
or 100 U BoNT-A. Of these, 13 (48%) patients recovered detrusor
contractility and ﬁve (19%) patients had a long-term therapeutic
effect without repeating the injection. This report supports the
voiding mechanism that relaxation of the external sphincter is an
intrinsic component of the voiding reﬂex.5. Conclusion
Voiding dysfunction is not an uncommon condition for young
men. Although the risk factors for this condition are still not
completely understood, uroﬂowmetry is recommended as an
important screening tool for patients with suspected voiding
dysfunction. A VUDS is suggested to make an accurate diagnosis in
cases of low urine ﬂow. PBNO and DV are the two most common
etiologies in young men with voiding dysfunction. The suggested
treatment options included medical treatment with an a-blocker,
surgical treatment with TUIBN, and urotherapy and/or baclofen for
DV. Several reports have shown the effect of BoNT-A injections on
voiding dysfunction in these patients. However, these studies
usually included small numbers of patients and lacked randomi-
zation and a control group. Further well-designed studies are
warranted to provide additional evidence of good management
techniques for voiding dysfunction in young men.Conﬂicts of interest statement
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